Document is current
Any future updates will be listed below
-
Authors
Campos, Adrian I. https://orcid.org/0000-0003-3468-8619
Byrne, Enda M.
Mitchell, Brittany L. https://orcid.org/0000-0002-9050-1516
Wray, Naomi R.
Lind, Penelope A. https://orcid.org/0000-0002-3887-2598
Licinio, Julio
Medland, Sarah E. https://orcid.org/0000-0003-1382-380X
Martin, Nicholas G. https://orcid.org/0000-0003-4069-8020
Hickie, Ian B.
Rentería, Miguel E. https://orcid.org/0000-0003-4626-7248
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (GNT1086683)
- License Information
-
More Information
Article History
Received: 23 June 2021
Revised: 10 January 2022
Accepted: 11 January 2022
First Online: 29 January 2022
Competing interests
: Professor Ian Hickie is the Co-Director, Health and Policy at the Brain and Mind Centre (BMC) University of Sydney, Australia. The BMC operates an early-intervention youth services at Camperdown under contract to headspace. Professor Hickie has previously led community-based and pharmaceutical industry-supported (Wyeth, Eli Lily, Servier, Pfizer, AstraZeneca) projects focused on the identification and better management of anxiety and depression. He is the Chief Scientific Advisor to, and a 5% equity shareholder in, InnoWell Pty Ltd. InnoWell was formed by the University of Sydney (45% equity) and PwC (Australia; 45% equity) to deliver the $30 M Australian Government-funded Project Synergy (2017–20) and to lead transformation of mental health services internationally through the use of innovative technologies. The remaining authors have nothing to disclose.
: The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. All protocols and questionnaires were approved by the QIMR Human Research Ethics Committee.
